News
Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...
Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...
Suspicious Ozempic products should be reported to Novo Nordisk or directly to the FDA. In addition, any adverse effects from ...
But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which ...
Novo Nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out ...
In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, ...
Novo Nordisk's booming obesity drugs & diabetes portfolio make it a top growth play. Click here to read an analysis of NVO ...
2d
Pharmaceutical Technology on MSNFDA free to pursue semaglutide compounders after latest court rulingDespite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...
The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...
Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.
The U.S. Food and Drug Administration (FDA) and drug manufacturer Novo Nordisk are warning consumers about “counterfeit” Ozempic found outside the authorized drug supply chain. The contents of the ...
Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results